September 12, 2025 - 03:18

Next Technology has announced a strategic move to implement a 200-for-1 reverse stock split, effective September 16. This decision will significantly reduce the company's outstanding shares from approximately 551.5 million to just 2.7 million. The reverse split is aimed at enhancing the company's stock price and improving its overall market appeal.
By consolidating shares, Next Technology aims to streamline its capital structure and potentially attract new investors who may have been deterred by a lower share price. The company will maintain its listing on NASDAQ, which is crucial for its visibility and accessibility to a broader range of investors.
As part of this transition, the company will also adopt a new CUSIP number: 961884301. This move is expected to bolster investor confidence and position Next Technology for future growth opportunities in a competitive market landscape. The management team is optimistic that this strategic decision will pave the way for improved financial performance moving forward.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...